Featured 13F manager
Merck & Co., Inc.
Rahway, NJ 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $526M
- 13 Positions
- 2026 Q2
- +50.7% QoQ
- Top 5 93.3%
Merck & Co., Inc. files a Form 13F. The latest book is 2026 Q2 at $526M, up 50.7% QoQ, led by Personalis, Moderna, and Kymera Therapeutics.
Portfolio
top 5 93.3% · top 10 99.8%
- PSNL - Personalis 35.8%
- MRNA - Moderna 30.7%
- KYMR - Kymera Therapeutics 16.8%
- AKTS - Aktis Oncology 5.9%
- EIKN - Eikon Therapeutics 4.1%
- TRDA - Entrada Therapeutics 2.4%
- STRO - Sutro Biopharma 1.7%
- ALEC - Alector 1.4%
- Evaxion Biotech A/S 0.7%
- Viridian Therapeutics 0.3%
- Xilio Therapeutics 0.2%
- Tuhura Biosciences 0.0%
- Other 0.0%
AUM over time
Latest book
| PSNL - Personalis | 35.75% | Hold | 14,044,943 | $13.40 | $188M | — | — |
| MRNA - Moderna | 30.71% | Hold | 2,308,190 | $70.03 | $162M | — | — |
| KYMR - Kymera Therapeutics | 16.82% | Hold | 772,165 | $114.67 | $89M | — | — |
| AKTS - Aktis Oncology | 5.83% | Hold | 952,844 | $32.23 | $31M | — | — |
| EIKN - Eikon Therapeutics | 4.13% | Hold | 1,666,666 | $13.05 | $22M | — | — |
| TRDA - Entrada Therapeutics | 2.43% | New | 1,739,768 | $7.36 | $13M | +1,739,768 | +$13M |
| STRO - Sutro Biopharma | 1.72% | New | 272,351 | $33.20 | $9M | +272,351 | +$9M |
| ALEC - Alector | 1.35% | Hold | 3,545,719 | $2.01 | $7M | — | — |
| Evaxion Biotech A/S | 0.71% | New | 1,214,126 | $3.10 | $4M | +1,214,126 | +$4M |
| Viridian Therapeutics | 0.33% | Hold | 93,414 | $18.37 | $2M | — | — |
| Xilio Therapeutics | 0.19% | Hold | 105,982 | $9.58 | $1M | — | — |
| Tuhura Biosciences | 0.01% | Hold | 19,445 | $2.34 | $46K | — | — |
| Neuphoria Therapeutics | 0.01% | Hold | 10,027 | $4.37 | $44K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2026 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| TRDA - Entrada Therapeutics | 6.28% | Exit | 0 | $12.62 | $22M | −1,739,768 | −$22M |
| Sutro Biopharma | 1.94% | Exit | 0 | $24.91 | $7M | −272,351 | −$7M |
| Evaxion Biotech A/S | 1.29% | Exit | 0 | $3.72 | $5M | −1,214,126 | −$5M |
| Carisma Therapeutics | 0.01% | Exit | 0 | $0.0326 | $48K | −1,473,240 | −$48K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 13 | $526M | +50.7% | 13F-HR | 8/7/2026 | 000031015826000210 |
| 2026 Q1 | 14 | $349M | +26.4% | 13F-HR | 5/13/2026 | 000031015826000141 |
| 2025 Q4 | 12 | $276M | +21.1% | 13F-HR | 2/17/2026 | 000031015826000055 |
| 2025 Q3 | 13 | $228M | — | 13F-HR | 11/12/2025 | 000031015825000063 |
About
Merck & Co., Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2